# VRCA earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/VRCA) · [Earnings tab](https://www.lopjlb.com/stock/VRCA?tab=earnings)

Updated: 2026-11-12T06:56:38

Quarters analyzed: 8

## Cross-quarter narrative

Across eight quarters, Verrica has transitioned from early commercial launch to accelerating YCANTH adoption with strengthening financial footing. YCANTH revenue grew from $3.2M in Q1 2024 to $5.9M in Q2 2026, with unit growth accelerating from 12% sequential (Q4 2024) to 51% YoY (Q1 2026) and 28% QoQ (Q2 2026). The permanent J-Code (April 2024) and 228M covered lives established reimbursement foundation. Pipeline advanced: VP-315 Phase II showed 51% histologic clearance in BCC (Q2 2024) and 97% ORR (Q4 2024); common warts Phase III initiated dosing December 2025, reached >50% enrollment by Q1 2026, with mid-2027 data target. FDA aligned on dual 100-subject BCC Phase III trials (Q3 2025). Financial discipline improved: 50% OpEx reduction (Q4 2024), GAAP profitability achieved (Q2 2025), $42M raise extended runway to 2026, then $27.5M nondilutive financing pushed runway to 2028 (Q2 2026). Torii partnership deepened from planned Phase III to secured global funding. EU filing targeted Q4 2026; Israel distribution deal signed Q2 2026. Cash concerns persisted but progressively resolved through operational improvements and strategic financing. Commercial execution risk shifted from reimbursement uncertainty to scaling demand; clinical risk remains around Phase III readouts. Management tone consistently positive (0.3-0.7), emphasizing milestone delivery.

## Latest CallCard · Q2

Verrica reports 28% QoQ YCANTH unit growth, $5.9M Q2 revenue, advances common warts Phase III (mid-2027 data), secures $27.5M nondilutive financing extending runway to 2028, and signs Israel distribution deal.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Prepared remarks emphasize major progress, stron

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2026 Q2:** Verrica reports 28% QoQ YCANTH unit growth, $5.9M Q2 revenue, advances common warts Phase III (mid-2027 data), secures $27.5M nondilutive financing extending runway to 2028, and signs Israel distribution deal.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Prepared remarks emphasize major progress, stron
- **2026 Q1:** Verrica reports accelerating YCANTH demand (15.3K units, +51% YoY), advances common warts Phase III (>50% enrolled) and VP-315 BCC program toward Phase III, cash runway into Q1 2027.','tone':{'mgmt':0.7,'mgmt_rationale':'Management highlights record dispensed units, April growth, pipeline milestones
- **2025 Q3:** Verrica reports Q3 YCANTH unit growth of 5% QoQ, 120% YoY; advances Phase III for common warts (dosing Dec) and BCC (FDA aligned on 2x100-subject trials); EU filing target Q4'26; cash $21M funds ops into late Q4.','tone': {'mgmt': 0.3, 'mgmt_rationale': 'Management highlights multiple milestones ach
- **2025 Q2:** Verrica reports 33% sequential YCANTH unit growth, secures Torii funding for global Phase III warts program, achieves GAAP profitability, but cash runway remains tight pending milestones.','tone': {'mgmt': 0.6, 'mgmt_rationale': 'CEO highlights record YCANTH growth, strategic Torii amendment providi
- **2024 Q4:** Verrica reports Q4 YCANTH unit growth of 12% sequentially, 50% OpEx reduction, $42M raise extends cash into 2026; advancing common warts Phase 3 with Torri (mid-2025 start) and VP-315 BCC with 97% ORR, awaiting FDA feedback.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Management highlights successful 
- **2024 Q2:** Verrica reports Q2 YCANTH revenue $4.9M (54% from Cencora stock order), 93% gross margin, cash runway into Q1 2025; VP-315 Phase 2 shows 51% histologic clearance in BCC; common warts Phase 3 planned H1 2025 with Torii.','tone': {'mgmt': 0.3, 'mgmt_rationale': 'Management highlights progress on YCANT
- **2024 Q1:** Verrica reports $3.2M YCANTH Q1 revenue, permanent J-Code effective April 1, 228M lives covered, NCE status, pediatric sales force deployed, VP-315 Phase II data expected Q2, common warts Phase III with Torii planned 2025, cash runway into Q1 2025.','tone':{'mgmt':0.7,'mgmt_rationale':'Prepared rema
- **2023 Q4:** —

## Theme arcs

- **YCANTH commercial traction** (improving): Revenue grew from $3.2M to $5.9M quarterly; unit growth accelerated from 12% sequential to 51% YoY and 28% QoQ; permanent J-Code and 228M covered lives established
- **Common warts Phase III progress** (improving): Advanced from H1 2025 planned start to dosing initiated Dec 2025, >50% enrolled by Q1 2026, mid-2027 data target; Torii global funding secured
- **VP-315 BCC development** (improving): Phase II 51% histologic clearance and 97% ORR reported; FDA aligned on dual 100-subject Phase III trials; program advancing toward Phase III initiation
- **Cash runway and financial resilience** (improving): Runway extended from Q1 2025 to 2026 ($42M raise), to Q1 2027, to 2028 ($27.5M nondilutive); GAAP profitability achieved; OpEx cut 50%
- **Torii partnership depth** (improving): Evolved from planned Phase III collaboration to secured funding for global warts program; strategic amendment providing financial support
- **Regulatory and geographic expansion** (new): EU filing target Q4 2026 established; Israel distribution deal signed; NCE status confirmed; FDA alignment on BCC trial design
- **Cost structure optimization** (improving): 50% OpEx reduction implemented; GAAP profitability achieved; 93% gross margin maintained
- **Revenue quality and durability** (improving): Early reliance on Cencora stock order (54% of Q2 2024 revenue) replaced by accelerating organic unit demand growth

## Guidance path

2023 Q4:vague → 2024 Q1:vague → 2024 Q2:vague → 2024 Q4:vague → 2025 Q2:vague → 2025 Q3:vague → 2026 Q1:vague → 2026 Q2:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/VRCA`